GENE ONLINE|News &
Opinion
Blog

2021-10-03|

Checkpoint Inhibitors as Part of Neoadjuvant Therapy in TNBC: Should We Use Them or Not?

by Joy Lin
Share To
Triple-negative breast cancer (TNBC) is a tough nut to crack, being a type of cancer with many mutations. TNBC, which comprises around 15% of breast cancers, carries a high mortality rate, and few treatments improve the odds of survival.

Cancer cells evade the immune system by stimulating immune checkpoints. Several studies have shown that highly mutated cancers may be more sensitive to treatment when checkpoint inhibitors are added in neoadjuvant therapy -- the medication given before the main treatment to shrink the tumor to more manageable levels. However, other studies are more cautious about the clinical benefits of checkpoint inhibition.

Recently at the 2021 ESMO Virtual Congress, experts debated whether or not to use immune checkpoint inhibitors as part of neoadjuvant therapy. The session was chaired by Dr. Sibylle Loibl, CEO of the German Breast Cancer Group, a leading group in breast cancer research.

GO Prime with only $1.49 now

LATEST
University of Pittsburgh Study Finds Flu Vaccines Prevent Up to 41.5 Percent of Infections in Simulated Communities
2025-07-19
Pharmacist-Led Initiatives Boost Pneumococcal Vaccine Uptake Among Older Adults Through Education and Direct Immunization Services
2025-07-19
Study Finds Agricultural Dust Exposure Alters Gut Microbiota and Weakens Intestinal Barrier in Mice
2025-07-19
Biotech Leaders Urge FDA to Reject Conservative Report Criticizing Mifepristone Safety Profile
2025-07-19
Physician Calls for Better Diagnosis of Cannabinoid Hyperemesis Syndrome Amid Discussions on Drug Pricing and Accessibility
2025-07-19
Maternal Vaccination Linked to Reduced RSV Hospitalizations in Newborns
2025-07-18
FDA Advisory Committee Votes Against Approval of GSK’s Blenrep Ahead of PDUFA Date
2025-07-18
EVENT
2025-07-23
BIO Asia–Taiwan 2025
Taipei, Taiwan
2025-08-08
HEALTHY AGEING TECH SHOW
Taipei, Taiwan
2025-08-09
MEDINFO 2025
Taipei, Taiwan
2025-09-03
BIO ASIA PACIFIC 2025
Bangkok, Thailand
2025-09-10
BIOHK 2025
Hong Kong
2025-10-01
Medical Japan 2025
Osaka, Japan
Scroll to Top